First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study

First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study

IntroductionPembrolizumab stands as a first-line option for patients with advanced non-small cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression (PD-L1 ≥50%). Several factors such as antibiotic exposure, low body mass index (BMI), certain metastatic location or poor perfor...

Full description

Saved in:
Bibliographic Details
Main Authors: Aida Piedra, Sergio Martínez-Recio, Ainhoa Hernández, Teresa Morán, Edurne Arriola, Jordi Recuero-Borau, Manuel Cobo, Patricia Cordeiro, Joaquín Mosquera, Manuel Fernández, Rosario García-Campelo, Antonio Calles, Rosa Álvarez, María Zapata-García, Dolores Isla, Ana Callejo, Patricia Iranzo, Jorgina Serra-López, Andrés Barba, Ivana Sullivan, Enriqueta Felip, Margarita Majem
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Oncology
Subjects:
pembrolizumab
non-small cell lung cancer
first-line
predictive factors
high PD-L1 expression
immune check-point inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1510278/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1510278/full

Similar Items